| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 05/10/2002 | WO2002036626A1 Single-chain multimeric polypeptides |
| 05/10/2002 | WO2002036612A1 Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane-associating elements |
| 05/10/2002 | WO2002036169A2 Methods and compositions for enhanced delivery of bioactive molecules |
| 05/10/2002 | WO2002036167A1 Formulations comprising dextrin polymers in combination with sugars for the delivery of nucleic acids |
| 05/10/2002 | WO2002036161A2 Novel targeted compositions for diagnostic and therapeutic use |
| 05/10/2002 | WO2002036160A2 Method for obtaining antigenic structures enhancing specific cross reactivity |
| 05/10/2002 | WO2002036152A1 Use of il-1 inhibitors and tnf antagonists, partially in combination with recombinant erythropoietins, for the treatment of anemia |
| 05/10/2002 | WO2002036145A2 Kahalalide f formulation |
| 05/10/2002 | WO2002036110A2 Oral self-emulsifying formulations of pyranone protease inhibitors |
| 05/10/2002 | WO2002036106A2 Novel medicament compositions based on anticholinergics and corticosteroids |
| 05/10/2002 | WO2002036104A2 Inhalative solution formulation containing a tiotropium salt |
| 05/10/2002 | WO2002036103A1 Transdermal drug delivery system with improved water absorbability and adhesion properties |
| 05/10/2002 | WO2002036101A1 Novel dispersible and soluble galenic paracetamol formulation, method for its preparation and its applications |
| 05/10/2002 | WO2002036098A1 Method and preparation for binding acetaldehyde in saliva, stomach and large intestine |
| 05/10/2002 | WO2002036097A2 Delivery system for entrapping charged macromolecules and a method for preparing same |
| 05/10/2002 | WO2002036073A2 Receptor antagonist-lipid conjugates and delivery vehicles containing same |
| 05/10/2002 | WO2002036067A2 Long-acting cytokine derivatives and pharmaceutical compositions comprising them |
| 05/10/2002 | WO2002020663A3 Degradable polyacetal polymers |
| 05/10/2002 | WO2002020057A3 Flavoring systems for pharmaceutical compositions and methods of making such compositions |
| 05/10/2002 | WO2002011743B1 Treatment of prostate cancer |
| 05/10/2002 | WO2002003954A3 Non swellable suppository comprising at least one biocompatible, non-biodegradable polymer and a controlled release formulation |
| 05/10/2002 | WO2002000246A3 Preparation containing an oxygen carrier for regeneration of the skin in the case of oxygen deficiency |
| 05/10/2002 | WO2001097813A3 Highly concentrated stable meloxicam solutions |
| 05/10/2002 | WO2001093890B1 Botulinum toxin implant |
| 05/10/2002 | WO2001093827B1 Neurotoxin implant |
| 05/10/2002 | WO2001091727A3 Self-emulsifying active substance formulation and use of this formulation |
| 05/10/2002 | WO2001091722A3 Water-thin emulsions with low emulsifier levels |
| 05/10/2002 | WO2001091718A3 Occlusive transdermal therapeutic system wit a non-occlusive backing layer |
| 05/10/2002 | WO2001088116A3 Method of modulating activation of lymphocytes via modulation of pituitary tumor transforming gene, related screeining methods |
| 05/10/2002 | WO2001085143A3 Pharmaceutical compositions for transdermal administration of anti-inflammatory agents |
| 05/10/2002 | WO2001078785A3 Active substance conjugates with intracellularly active ligands |
| 05/10/2002 | WO2001077145A3 Integrin binding peptide derivatives |
| 05/10/2002 | WO2001076639A3 Chemically-modified myelopoietin conjugates |
| 05/10/2002 | WO2001074329A3 Sustained release beadlets containing stavudine |
| 05/10/2002 | WO2001064650A3 Synthesis of epothilones, intermediates thereto and analogues thereof |
| 05/10/2002 | WO2001064236A3 METHODS FOR TREATING FSH RELATED CONDITIONS WITH GnRH ANTAGONISTS |
| 05/10/2002 | WO2001064214A3 Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors |
| 05/10/2002 | WO2001051087A3 Novel treatment for eye disease |
| 05/10/2002 | WO2001045796A3 Method for the preparation of 1-benzotriazolyl carbonate esters of poly(ethylene glycol) |
| 05/10/2002 | WO2001045745A3 A reversible linkage technology for controlled conjugation |
| 05/10/2002 | WO2001043779A3 Anti-hiv-1 conjugates for treatment of hiv disease |
| 05/10/2002 | WO2001042472A3 DNA ENCODING A NOVEL PROST-Ets POLYPEPTIDE |
| 05/10/2002 | WO2001039725A3 Drug preparations |
| 05/10/2002 | WO2001036487A3 Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
| 05/10/2002 | WO2001034117A9 A method for chemoprevention of prostate cancer |
| 05/10/2002 | WO2001028522A3 Method for producing liposome preparation |
| 05/10/2002 | WO2001026629A3 Neutral-cationic lipid for nucleic acid and drug delivery |
| 05/10/2002 | WO2001000246A3 Hydrogels derived from chitosan and poly(ethylene glycol) |
| 05/10/2002 | WO2000067761A8 Compositions and methods for identifying antigens which elicit an immune response |
| 05/10/2002 | WO2000054802A3 Method of expressing antigens on the surface of antigen presenting cells by photochemical internalization |
| 05/10/2002 | CA2428606A1 Novel targeted compositions for diagnostic and therapeutic use |
| 05/10/2002 | CA2427539A1 Method for obtaining antigenic structures enhancing specific cross reactivity |
| 05/10/2002 | CA2426967A1 Delivery system for entrapping charged macromolecules and a method for preparing same |
| 05/10/2002 | CA2426047A1 Therapeutic oligonucleotides of reduced toxicity |
| 05/10/2002 | CA2426012A1 Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane-associating elements |
| 05/10/2002 | CA2425842A1 Use of il-1 inhibitors and tnf antagonists, partially in combination with recombinant erythropoietins, for the treatment of anemia |
| 05/10/2002 | CA2425627A1 Kahalalide f |
| 05/09/2002 | WO2002036591A2 Inhalative solution formulation containing a tiotropium salt |
| 05/09/2002 | US20020055667 Absorbable brachytherapy and chemotherapy delivery devices and methods |
| 05/09/2002 | US20020055666 Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors |
| 05/09/2002 | US20020055573 Stabilized monomer adhesive compositions |
| 05/09/2002 | US20020055562 Gel compositions |
| 05/09/2002 | US20020055542 E.g., phenylbutyric acid; for treating a subject having an ulcer or radiation fibrosis. |
| 05/09/2002 | US20020055531 Methods for treatment of inflammatory diseases |
| 05/09/2002 | US20020055512 Release rate controlling substance; treating metabolic syndrome, diabetes mellitis type II or symptoms |
| 05/09/2002 | US20020055503 Treatment of seizures resulting from, e.g. epileptic attack. |
| 05/09/2002 | US20020055481 DNA that represents the splicing enhancer sequence (SES) in exon 45 of human dystrophin gene, and serves as a template in preparation of the antisense oligonucleotide, which is used to induce exon 45 skipping |
| 05/09/2002 | US20020055477 Immunomodulatory formulations and methods for use thereof |
| 05/09/2002 | US20020055464 Polyacid glycopeptide derivatives |
| 05/09/2002 | US20020055460 Adminstering a compound that binds to a receptor for the glucagon-like peptide-1 (GLP-1) |
| 05/09/2002 | US20020055419 System and method to improve fitness training |
| 05/09/2002 | US20020055185 Solid support for use as ligand for amplifying or detecting and/or confining target particles |
| 05/09/2002 | US20020055174 Complex for transferring an anionic substance of interest into a cell |
| 05/09/2002 | US20020054915 Prolonged anesthesia in joints and body spaces |
| 05/09/2002 | US20020054907 Multiparticulate modified release composition |
| 05/09/2002 | US20020054905 A starch polysaccharide having a tap density of < 0.2 g/ml, when used in an binding in a tablet, prevents the crushing strength of tablet from decreasing more than 20% decrease in crushing strengh when exposed to 95% relative humidity |
| 05/09/2002 | US20020054904 Stable pergolide mesylate and process for making same |
| 05/09/2002 | US20020054902 Liposomes containing therapeutic genes are conjugated to targeting agents to provide transport of encapsulated gene across blood-retainal barrier and plasma membrane of ocular cell, where this gene expresses encoded therapeutical agent |
| 05/09/2002 | US20020054900 Barrier layer positioned over composite layer and being of thickness adequate to provide controlled release of bioactive agent, barrier layer being applied by low energy plasma polymerization |
| 05/09/2002 | US20020054896 Applying onto healed wound a composition comprising a fluid, film-forming carrier, and subsequently hardening the carrier into a tangible membrane juxtaposed to the healed wound thereby reducing scarring or improving the appearance thereof |
| 05/09/2002 | US20020054895 And at least one anionic or nonionic emulsifier that is substantially hydrophilic and is soluble in water; skin protectants |
| 05/09/2002 | US20020054894 Composition comprising a hydrophilic component and a combination of a volatile compound and a pasty fatty compound, and use thereof |
| 05/09/2002 | US20020054893 Method and agent for enhancing diffusivity and long-lasting property of fragrance |
| 05/09/2002 | US20020054881 Variants can be used in specific immunotherapy of allergic pathologies caused by dust mites |
| 05/09/2002 | US20020054879 Reacting protein with polysaccharide to produce mixture including protein-polysaccharide conjugate and free protein |
| 05/09/2002 | US20020054868 Bacterial strain, processes plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications |
| 05/09/2002 | US20020054867 A probiotic formulation of Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799); containing at least one volatile fraction (VF) of a plant extract |
| 05/09/2002 | US20020054866 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications |
| 05/09/2002 | US20020054863 Method of treating cancerous tumors with a dendritic-platinate drug delivery system and a process for preparing that system |
| 05/09/2002 | US20020054852 A carrier material reflects or absorbs or emits electromagnetic or mechanical vibration enabling the monitoring of carrier material and a drug associated with carrier, and a targeting agent bind to the site |
| 05/08/2002 | EP1203591A1 Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| 05/08/2002 | EP1203589A1 Use of terpene alcohol ethoxylates as solubilizers in cosmetic or pharmaceutical formulations or in concentrates for food compositions |
| 05/08/2002 | EP1203581A2 Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| 05/08/2002 | EP1203531A2 Water soluble compositions containing chlorhexidine and their use |
| 05/08/2002 | EP1203084A1 Microencapsulated nitric oxide synthase source |
| 05/08/2002 | EP1203026A1 Binding moieties for fibrin |
| 05/08/2002 | EP1203004A1 HIGH AFFINITY TGF$g(g) NUCLEIC ACID LIGANDS AND INHIBITORS |
| 05/08/2002 | EP1203002A1 Process for preparing a charcoal-gm1 complex |
| 05/08/2002 | EP1202996A1 Titanium derived compounds, preparation and use thereof |
| 05/08/2002 | EP1202982A1 Method for preparing a gamma-unsaturated beta-lactone and use thereof as an aromatic and flavouring ingredient |